Thromb Haemost 2002; 87(03): 543-544
DOI: 10.1055/s-0037-1613041
Letters to the Editor
Schattauer GmbH

Detection of Transfused Platelets in a Patient with Glanzmann Thrombasthenia

Alan Nurden
1   UMR 5533 CNRS, Laboratoire d’Hémobiologie, Hôpital Cardiologique, 33604 Pessac, France
,
Robert Combrié
1   UMR 5533 CNRS, Laboratoire d’Hémobiologie, Hôpital Cardiologique, 33604 Pessac, France
,
Paquita Nurden
1   UMR 5533 CNRS, Laboratoire d’Hémobiologie, Hôpital Cardiologique, 33604 Pessac, France
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 19. November 2001

Accepted 20. November 2001

Publikationsdatum:
14. Dezember 2017 (online)

 

 
  • References

  • 1 Poon MC. Use of recombinant factor VIIa in hereditary bleeding disorders. Thromb Haemost 2001; 08: 312-8.
  • 2 D’Oiron R, Menart C, Trzeciak MC, Nurden P, Fressinaud E, Dreyfus M, Laurian Y, Negrier C. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
  • 3 Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopenia. Semin Thromb Hemost 2000; 26: 373-7.
  • 4 Nurden AT, George JN. Inherited abnormalities of the platelet membrane: Glanzmann thrombasthenia, Bernard-Soulier syndrome, and other disorders. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Philadelphia, Lippincott: Williams & Wilkins; 2000: 921-43.
  • 5 French DL. The molecular genetics of Glanzmann’s thrombasthenia. Platelets 1998; 09: 5-20.
  • 6 Rosa JP, Kieffer N, Didry D, Pidard D, Kunicki TJ, Nurden AT. The human platelet membrane glycoprotein complex GPIIb-IIIa expresses antigenic sites not exposed on the dissociated glycoproteins. Blood 1984; 64: 1246-54.
  • 7 Jallu V, Diaz-Ricart M, Ordinas A, Pico M, Vezon G, Nurden AT. Two human antibodies reacting with different epitopes on integrin β3 of platelets and endothelial cells. Eur J Biochem 1994; 222: 743-51.
  • 8 Ishida F, Gruel Y, Broier E, Nugent DJ, Kunicki TJ. Repertoire cloning of a human IgG inhibitor of αIIb β3 function. The OG idiotype. Mol Immunol 1995; 32: 613-22.
  • 9 Nurden AT, Ruan J, Pasquet J-M, Gauthier B, Combrié R, Kunicki TJ, Nurden P. A novel Leu196 to Pro substitution in the β3 subunit of the αIIbβ3 integrin in a patient with a variant form of Glanzmann thrombasthenia (submitted)..
  • 10 Pidard D, Montgomery RR, Bennett JS, Kunicki TJ. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets. J Biol Chem 1983; 258: 12582-6.
  • 11 Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coag Fibrin 1993; 04: 729-37.
  • 12 Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8.
  • 13 Ndoko S, Poujol C, Combrié R, Nurden A, Nurden P. Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes. Thromb Haemost 2002; 87 (02) 317-22.
  • 14 Bihour C, Durrieu-Jais C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT. Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999; 19: 212-9.